These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 21402544)
1. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. Shi D; Yang D; Prinssen EP; Davies BE; Yan B J Infect Dis; 2011 Apr; 203(7):937-42. PubMed ID: 21402544 [TBL] [Abstract][Full Text] [Related]
2. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Zhu HJ; Markowitz JS Drug Metab Dispos; 2009 Feb; 37(2):264-7. PubMed ID: 19022936 [TBL] [Abstract][Full Text] [Related]
3. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Shi J; Wang X; Eyler RF; Liang Y; Liu L; Mueller BA; Zhu HJ Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):555-561. PubMed ID: 27228223 [TBL] [Abstract][Full Text] [Related]
4. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. Shi D; Yang J; Yang D; LeCluyse EL; Black C; You L; Akhlaghi F; Yan B J Pharmacol Exp Ther; 2006 Dec; 319(3):1477-84. PubMed ID: 16966469 [TBL] [Abstract][Full Text] [Related]
5. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Yang D; Pearce RE; Wang X; Gaedigk R; Wan YJ; Yan B Biochem Pharmacol; 2009 Jan; 77(2):238-47. PubMed ID: 18983829 [TBL] [Abstract][Full Text] [Related]
7. Effects of alcohol on human carboxylesterase drug metabolism. Parker RB; Hu ZY; Meibohm B; Laizure SC Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794 [TBL] [Abstract][Full Text] [Related]
8. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. Boberg M; Vrana M; Mehrotra A; Pearce RE; Gaedigk A; Bhatt DK; Leeder JS; Prasad B Drug Metab Dispos; 2017 Feb; 45(2):216-223. PubMed ID: 27895113 [TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition. Hu ZY; Edginton AN; Laizure SC; Parker RB Clin Pharmacokinet; 2014 Sep; 53(9):825-36. PubMed ID: 25103325 [TBL] [Abstract][Full Text] [Related]
10. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607 [TBL] [Abstract][Full Text] [Related]
11. The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. Oh J; Lee S; Lee H; Cho JY; Yoon SH; Jang IJ; Yu KS; Lim KS PLoS One; 2017; 12(4):e0176320. PubMed ID: 28437488 [TBL] [Abstract][Full Text] [Related]
13. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Zhu HJ; Appel DI; Jiang Y; Markowitz JS Drug Metab Dispos; 2009 Sep; 37(9):1819-25. PubMed ID: 19487248 [TBL] [Abstract][Full Text] [Related]
14. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. Walter Soria N; Belaus A; Galván C; Ana Pasquali M; Velez P; Del Carmen Montes C; Beltramo DM Genet Test Mol Biomarkers; 2010 Dec; 14(6):749-51. PubMed ID: 20858053 [TBL] [Abstract][Full Text] [Related]
15. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Thomsen R; Rasmussen HB; Linnet K; Drug Metab Dispos; 2014 Jan; 42(1):126-33. PubMed ID: 24141856 [TBL] [Abstract][Full Text] [Related]
16. Examination of the carboxylesterase phenotype in human liver. Ross MK; Borazjani A; Wang R; Crow JA; Xie S Arch Biochem Biophys; 2012 Jun; 522(1):44-56. PubMed ID: 22525521 [TBL] [Abstract][Full Text] [Related]
17. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Merali Z; Ross S; Paré G Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246 [TBL] [Abstract][Full Text] [Related]
18. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Wang X; Wang G; Shi J; Aa J; Comas R; Liang Y; Zhu HJ Pharmacogenomics J; 2016 Jun; 16(3):220-30. PubMed ID: 26076923 [TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir. Zhang Q; Melchert PW; Markowitz JS Chem Biol Interact; 2022 Sep; 365():110097. PubMed ID: 35964681 [TBL] [Abstract][Full Text] [Related]
20. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Ishizuka T; Yoshigae Y; Murayama N; Izumi T Drug Metab Dispos; 2013 Nov; 41(11):1888-95. PubMed ID: 23946449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]